celiac disease and glp 1 Causes Risk Factors Common ground: shared risk factors

Januvia is a DDP-4 inhibitor and is used to treat type 2 diabetes in adults

Recent Developments in May 2026 & Recent Industry Updates:- In May 2025, #BauschHealthandSalixPharmaceuticals announced new findings showing that #Xifaxan (rifaximin) treatment following #OvertHepaticEncephalopathy hospitalization was associated with a reduced risk of 30-day OHE-related rehospitalization

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes

It is information that directly affects what any compounded GLP-1 platform can offer right now, and skipping it is the mistake that leads to enrollment decisions people regret

While more research is needed, the current evidence supports B12 as a treatment for nerve pain

The agency highlighted risks including dosing errors, contamination, and the use of unapproved salt forms in compounded versions, some of which resulted in adverse events requiring hospitalizations.[3] This followed previous statements by the FDA concerning unapproved GLP-1 drugs used for weight loss, including concerns with compounded versions of the drug, fraudulent compounded GLP-1 drugs, and versions sold falsely for research purposes or not for human consumption.[4] Import Alert 66-80 now ties enforcement to the Green List by authorizing detention without physical examination of GLP-1 API shipments from non-listed firms